US SEC Trading Suspension Halt Orders — July 31, 2026

31-07-2026

Upexi, Inc. received a Nasdaq deficiency notice on July 30, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days (June 16 – July 29, 2026). The company has a 180-day compliance period until January 26, 2027, to regain compliance, and may consider a reverse stock split. Failure to cure could lead to delisting, though an additional 180-day period may be available if certain conditions are met.

• · Non-compliance period: June 16, 2026 through July 29, 2026.
• · Initial compliance deadline: January 26, 2027.
• · If a reverse stock split is used, it must be completed at least 10 business days before the compliance deadline.
• · An additional 180-day compliance period may be available if the company meets all other initial listing standards for the Nasdaq Capital Market.

31-07-2026

Humacyte, Inc. received a Nasdaq Staff notice on July 31, 2026, that its common stock (HUMA) has failed to maintain the minimum $1.00 bid price for 30 consecutive business days, triggering a potential delisting. The company has a 180-day cure period until January 27, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. While the notice does not immediately affect trading or operations, the company faces significant uncertainty in meeting the listing requirement.

• · The notice was received on July 31, 2026, and the non-compliance period ended July 30, 2026.
• · The compliance deadline is January 27, 2027.
• · The company's common stock continues to trade on The Nasdaq Global Select Market under symbol 'HUMA'.
• · The company's redeemable warrants (HUMAW) are not mentioned as being affected by this notice.
• · The company intends to monitor the bid price and consider options to achieve compliance, but there is no assurance of success.

31-07-2026

Mira Pharmaceuticals, Inc. (MIRA) received a Nasdaq deficiency notice on July 27, 2026, for failing to maintain the minimum $1.00 bid price per share over 30 consecutive business days. The company has a 180-day cure period (until January 25, 2027) to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. While the stock continues trading on the Nasdaq Capital Market under the symbol MIRA, there is no assurance the company will be able to regain compliance, and failure could lead to delisting.

• · The deficiency letter was received on July 27, 2026, based on the 30 consecutive business days ended July 24, 2026.
• · If the company does not regain compliance within the initial 180-day period, it may be eligible for an additional 180-day compliance period if it meets other listing standards and provides written notice of intent to cure via a reverse stock split.
• · The company may appeal a delisting determination to a Nasdaq Hearings Panel, but there is no assurance of success.

31-07-2026

bioAffinity Technologies received a Nasdaq Staff Determination on July 30, 2026, for failing to meet the minimum bid price of $1.00 per share over the prior 30 consecutive business days. Because the company effected a 1-for-30 reverse stock split on September 19, 2025, it is not eligible for the standard 180-day compliance period. The company intends to appeal the determination on August 6, 2026, which will stay the delisting pending a panel decision, but there is no assurance of regaining compliance or maintaining the listing.

• · The company effected a 1-for-30 reverse stock split on September 19, 2025, which disqualifies it from the standard 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv).
• · The appeal must be submitted by August 6, 2026, to stay the delisting and suspension pending the Panel's decision.
• · The Staff Determination covers the period from June 16, 2026 through July 29, 2026.

31-07-2026

Context Therapeutics Inc. (CNTX) received a Nasdaq deficiency notice on July 29, 2026, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has an initial 180-day cure period until January 25, 2027, to regain compliance by achieving a $1.00+ closing bid price for 10 consecutive business days, with a potential second 180-day compliance period if eligible. The company intends to monitor its stock price and evaluate options, but there is no assurance of regaining compliance or avoiding delisting.

• · The deficiency notice has no immediate effect on Nasdaq listing or trading of CNTX common stock.
• · If compliance is not regained by January 25, 2027, the company may be eligible for a second 180-day compliance period, subject to meeting other initial listing standards and Nasdaq's belief that compliance can be regained.
• · If delisting is initiated, the company may appeal to a Nasdaq Hearings Panel, but success is not assured.

31-07-2026

DocGo Inc. received a Nasdaq letter granting an additional 180 calendar days, until January 25, 2027, to regain compliance with the minimum bid price requirement of $1.00 per share. The company's stockholders have approved a reverse stock split as a potential remedy, but there is no assurance of regaining compliance.

• · The company's common stock has a par value of $0.0001 per share.
• · To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days.
• · Stockholders approved a reverse stock split at ratios of 1-for-5, 1-for-6, 1-for-7, 1-for-8, 1-for-9, or 1-for-10, to be determined by the Board of Directors.
• · The reverse stock split was approved at the 2026 Annual Meeting of Stockholders held on June 16, 2026.

31-07-2026

Traws Pharma, Inc. (TRAW) received a Nasdaq deficiency notice on July 29, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, triggering a potential delisting. The company has a 180-day cure period until January 25, 2027, to regain compliance by closing at or above $1.00 for at least 10 consecutive business days. While the listing remains effective for now, failure to cure could lead to delisting, and the company is exploring options but cannot assure compliance.

• · The company may be eligible for a second 180-day grace period if it meets all other listing standards and notifies Nasdaq of its intent to cure.
• · If delisting proceeds, the company can appeal to a Nasdaq hearings panel.
• · The company's common stock trades under the symbol TRAW on The Nasdaq Capital Market.

31-07-2026

PDS Biotechnology Corp received a Nasdaq deficiency letter on July 30, 2026, because its common stock closing bid price remained below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement. The company has a 180-day compliance period until January 26, 2027, to regain compliance, and may consider a reverse stock split, but there is no assurance of success. The stock continues to trade under the symbol PDSB for now.

• · The deficiency letter was received on July 30, 2026, and the filing was made on July 31, 2026.
• · If compliance is not regained by January 26, 2027, the company may be eligible for a second 180-day compliance period if it meets other listing standards.
• · The company may consider a reverse stock split as a potential cure.
• · The stock continues to trade on the Nasdaq Capital Market under the symbol PDSB with no immediate delisting effect.